Cytena and its affiliate cytena Bioprocess Solutions part of CELLINK Life Sciences, announced that they will collaborate with AstraZeneca to develop a new generation of plate-based microbioreactors that can improve the efficiency of cell line development workflows. Cytena, which focuses on developing and commercializing innovative single-cell isolation and cultivation technologies, says that its collaboration with AstraZeneca will also explore machine learning algorithms for enhanced single-cell cloning. This collaboration will leverage Cytena’s recent technological advances in the field of single-cell isolation and bioprocessing to increase efficiency and shorten timelines in the discovery and production of therapeutic antibodies. Therapeutic antibodies are biopharmaceuticals widely used in the treatment of cancer, autoimmune and inflammatory diseases; they are also used for targeted drug delivery.
Cytena is a CELLINK company based in Freiburg, Germany, and Taipei, Taiwan.
Memory
SK Hynix shifts focus in China: Shanghai out, Wuxi in
Memory
Trymax: Receives multi-system orders from a large asian based foundry
Semiconductor Equipment
Intel industry’s first mover on High NA EUV lithography system
Computing and Software
What works best for chiplets
Computing and Software
Underappreciated EU suppliers lead the semiconductor equipment market
Global Semiconductor Trends
Yole Group Viewpoint – Exploring semiconductor equipment during a geopolitically charged era
Semiconductor Equipment
Mycronic receives order for an SLX mask writer
Computing and Software
FPGA market set for steady demand growth
Compound Semiconductor
Power GaN: harnessing new horizons
Semiconductor Equipment